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Background: Inﬂuenza virus causes annual epidemics in the winter–spring season with signiﬁcant morbidity in the
general population and important mortality in high-risk groups, including cancer patients. Opinions on the suitability of
patients with malignancies not undergoing active treatment and in different phases of antineoplastic therapy, to receive
inﬂuenza vaccination, vary considerably among oncologists, sometimes even within one center.
Methods:We reviewed available data, including recommendations by national health authorities, on impact of inﬂuenza
in patients with cancer and their capacity to mount protective immunological responses to vaccination, thus allowing, on
behalf of Italian Association of Medical Oncology, to make suitable recommendations for the prevention and treatment of
seasonal inﬂuenza.
Results and discussion: Patients with cancer often have disease- or treatment-related immunosuppression, and as a
consequence, they may have a suboptimal serologic response to inﬂuenza vaccination. The protective effect of the differ-
ent preparations of inﬂuenza vaccines in patients with cancer has not been widely investigated, especially in adult patients
harboring solid tumors. The optimal timing for administration of inﬂuenza vaccines in patients receiving chemotherapy is
also not clearly deﬁned. However, since vaccination is the most effective method, along with antiviral drugs in selected
patients, for preventing inﬂuenza infection, it has to be recommended for cancer patients. Implementing vaccination of
close contacts of oncology patients would be an additional tool for enhancing protection in fragile patient populations.
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introduction
Inﬂuenza virus is an enveloped virus belonging to the
Orthomixoviridae. Peculiar to this virus is the segmented and
single-stranded negative-sense RNA genome, which enhances
its potential for recombination. Three types of inﬂuenza virus
(A, B, and C) have been so far recognized, but only inﬂuenza
virus type A and B have been associated with seasonal epi-
demics, and only inﬂuenza virus type A can occasionally give
rise to worldwide pandemics [1].
Three HA antigens (H1, H2, and H3) and two NA antigens
(N1 and N2) of inﬂuenza A viruses have caused widespread
disease and sustained human-to-human transmission while, in
birds, 16 different HA antigens (H1–H16) and 9 NA antigens
(N1–N9) are currently known. Minor antigenic variants arise
yearly within the speciﬁc H1N1 and H3N2 subtypes during sea-
sonal epidemics. Inﬂuenza B viruses also undergo antigenic
drift and a signiﬁcant part of the annual inﬂuenza burden is
caused by two co-circulating, antigenically distinct lineages
called the Yamagata and Victoria lineages.
Inﬂuenza virus type A and B show similar pathogenic poten-
tial in humans, and co-circulate during seasonal epidemics.
More complex is the mechanism at the basis of pandemic
events. In these cases, major antigenic variants of inﬂuenza A
(antigenic shift) may be generated through genetic reassortment
between virus strains of human and avian origin (the largest res-
ervoir of inﬂuenza A strains) in host mammals susceptible to
both infections, such as swine. Viruses circulating in different
animal species may also be introduced directly into the human
population [2]. Avian inﬂuenza viruses of the H5, H7, and H9
subtypes have also been associated with sporadic infections in†PP, FB and ID equally contributed to the paper.
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humans. The level of herd immunity in humans to new reassor-
tant viruses is usually very low, making it possible their rapid
spread worldwide (pandemics) and underlies the increased
virulence of pandemic inﬂuenza A strains.
Inﬂuenza virus A and B are eliminated at high titer in respira-
tory secretions and are spread through droplets, but also
through contact with contaminated hands or objects.
It is generally assumed that both innate and adaptive immun-
ity play a role in controlling inﬂuenza virus infection at the indi-
vidual level. In particular, the presence of cross-reactive memory
B and T cells is responsible for the differing susceptibility to
inﬂuenza virus infection and disease severity, observed between
young people and adults. In Italy, data collected from the nation-
wide active sentinel surveillance network (INFLUNET) show that
among clinical swabs collected during 2010–2011 season, 31%
were tested positive for inﬂuenza (http://www.trovanorme.salute.
gov.it/norme/renderNormsanPdf?anno=0&codLeg=39451&parte=
1%20&serie=). The incidence of seasonal inﬂuenza decreases
with age and reaches a minimum value in healthy adults, which
correlates with the pre-existing inﬂuenza immunity.
Inﬂuenza infection can be limited at the upper respiratory
tract, but can also spread to the lower respiratory tract and cause
respiratory failure. In addition, lung failure can be exacerbated
by bacterial and fungal superinfections in debilitated indivi-
duals. When evaluating the effectiveness of inﬂuenza vaccine, it
is important to point out that, during the winter–spring season,
a number of respiratory viruses co-circulate together with
inﬂuenza A and B (rhinovirus, metapneumovirus, respiratory-
syncitial virus, enterovirus, coronavirus, adenovirus). In Italy,
seasonal inﬂuenza epidemics are associated with an annual
average of about 8000 excess deaths. In the 2010–2011 season,
6700 deaths (84%) were among elderly people aged ≥65 with
underlying cardiopulmonary conditions or other chronic
diseases.
Inﬂuenza infection is a potential cause of additional morbid-
ity and mortality in subjects who are immunocompromised
because of underlying disease or its therapy [3]. In fact, people
with cancer are more likely to get inﬂuenza complications such
as upper and lower respiratory tract infections. Hospitalization
because of inﬂuenza infections is three to ﬁve times higher in
cancer patients than in the general population, and the mortality
rate is 9% in oncology patients (relative risk of 4 compared with
the general population) [4]. As a consequence, the health au-
thorities recommend vaccination against inﬂuenza in the im-
munocompromised host and in close contacts [3]. Vaccination
is also important to prevent intercurrent infections that may
require dose reduction and delays in the treatment of the under-
lying malignancy.
The purpose of this article is to highlight the impact of
inﬂuenza in patients with cancer and their capacity to mount
protective immunological responses to vaccination, thus allow-
ing the Italian Association of Medical Oncology (AIOM) to
make suitable recommendations for the prevention and treat-
ment of seasonal inﬂuenza.
methods
We reviewed available data present in the literature, including recommenda-
tions by national health authorities, on impact of inﬂuenza in patients with
cancer and their capacity to mount protective immunological responses to
vaccination. Data on available vaccines, strategies to improve the efﬁcacy of
inﬂuenza vaccination, and treatment of established infection were also
reviewed.
In addition, experts from the Italian society of Virology and the Italian
Health Authority, who are listed among authors, provided additional bio-
logical, clinical, and epidemiologic information which greatly helped in clari-
fying some issues in the absence of clear-cut information from the literature.
results
available vaccines and their potential side-effects
Two types of inﬂuenza vaccines are available: (i) the inactivated,
injectable vaccine approved for use in subjects older than 6 months,
including healthy people, pregnant women, and people with
chronic medical conditions; (ii) the live attenuated inﬂuenza
vaccine (LAIV) administered as a nasal spray. LAIV is approved
for use in healthy people from 2 to 49 years of age who are not
pregnant. Trivalent inactivated Inﬂuenza vaccines may include
adjuvants to enhance immunogenicity, and are usually adminis-
tered as a single shot in immunocompetent individuals, while
immunosuppressed subjects may need booster administration.
Seasonal inﬂuenza vaccines contain antigens that match the
three different inﬂuenza strains co-circulating during the sea-
sonal epidemics (A H1N1, A H3N2, and inﬂuenza B). Due to
the constant emergence of antigenic drift variants under herd
immunity pressure, the Inﬂuenza vaccine needs yearly update to
include the escape variants detected during each seasonal epi-
demic which are predicted to circulate during the next winter–
spring season. This update is organized by the WHO through
the network of sentinel practitioners and reference laboratories
(INFLUNET). If the viruses in the vaccine are closely matched
to those circulating in the community, vaccine effectiveness is
greater. However, even when the viruses are not closely related,
the vaccine can still be expected to provide some cross-protection
against different, but related, strains of inﬂuenza viruses. Based
on the limited cross-protection between the two inﬂuenza B
lineages and the inability to accurately predict which inﬂuenza
B lineage will circulate, a quadrivalent inﬂuenza vaccine includ-
ing both inﬂuenza B strains [5] has recently been approved by
the FDA and the European Medicines Agency. Pharmaceutical
companies will likely transition to predominantly producing the
quadrivalent vaccine.
Over the years, hundreds of millions of people worldwide
have received seasonal inﬂuenza vaccines, essentially without
serious consequences. The most common side-effects reported
are soreness, redness, tenderness, or swelling of the injection
site. Less common are mild arthromyalgia, low-grade fever, and
nausea. When such problems occur, they start soon after vaccin-
ation and persist for1–2 days. On rare occasions, Inﬂuenza vac-
cination has been associated with more serious complications,
such as severe allergic reactions. Before inactivation, inﬂuenza
viruses are cultured in chicken eggs, so administration of
inﬂuenza vaccines in subjects with allergy to chicken egg pro-
teins should be avoided.
Inﬂuenza vaccination has been reported to increase the risk of
Guillain–Barré syndrome (GBS) up to 8.8-fold over background
rates, mainly based on the experience in 1976 when mass immun-
ization was conducted to prevent an A H1N1 inﬂuenza epidemic
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[6]. Enhanced surveillance for GBS, conducted in 2009–2010,
suggested that inﬂuenza vaccines were of public health beneﬁt,
albeit being associated with a small increased risk of GBS [6].
response and timing of vaccination
in cancer patients
Successful immunization depends on an intact immune system
that can produce antibodies and T-cell response upon antigen
exposure. Patients with cancer are considered functionally im-
munosuppressed, due to their underlying disease and/or cancer
therapy. As a consequence, they may have a suboptimal sero-
logic response to inﬂuenza vaccination. Although antiviral
prophylaxis has been recently used for prevention of inﬂuenza
virus infection in speciﬁc clinical settings such as perivaccine
prophylaxis, postexposure prophylaxis, family cluster prophy-
laxis, as well as seasonal prophylaxis [5], vaccination is the most
effective method for widespread prevention of inﬂuenza infec-
tion. Indeed, the CDC’s Advisory Committee on Immunization
Practice (ACIP) in the United States recommends seasonal in-
ﬂuenza vaccination for adults without contraindications, who
have disease- or medication-related immunosuppression (http://
www.cdc.gov/ﬂu/about/disease/high_risk.htm). However, knowl-
edge of serologic response to seasonal inﬂuenza vaccine remains
scanty in patients with cancer and is particularly sparse in those
with solid tumors [7]. Tumor heterogeneity, timing of inﬂuenza
vaccination relative to different chemotherapy treatments, and
a general lack of data concerning the vaccine efﬁcacy against
inﬂuenza infection, or its complications, make it difﬁcult to
compare the clinical studies so far reported in the literature. The
results of eight controlled clinical trials looking at the efﬁcacy of
inﬂuenza vaccination in pediatric cancer patients were reviewed
[8]. Children receiving chemotherapy were able to generate im-
mune responses to the vaccine, albeit more weakly than healthy
children, children with asthma or children with cancer who had
completed chemotherapy more than 1 month before vaccin-
ation. Inﬂuenza vaccine was safely administered, and there were
no reports of persistent adverse reactions in any of the studies,
although patients receiving chemotherapy had a higher inci-
dence of general malaise following vaccination. None of these
studies reported on clinical outcome. Seroprotection (antibody
titer >40) and seroconversion (at least a fourfold rise in HI
titers) were achieved in patients with an established diagnosis of
lymphoproliferative disorders [9, 10], irrespective of the previ-
ous chemotherapy administration.
Another recent review and meta-analysis conducted to assess
inﬂuenza vaccination in immunocompromised patients showed
a signiﬁcantly lower incidence of inﬂuenza-like illness after vac-
cination in HIV patients, cancer patients, and transplant recipi-
ents compared with placebo or no vaccination [11].
An early study investigated the serologic response to bivalent
inactivated inﬂuenza vaccination in 17 patients with malignan-
cies [12]. Protective immunity against each of the two inﬂuenza
A strains in the vaccine was achieved by 41% and 47% of
patients, respectively. A study conducted on 41 patients with
lung cancer showed a rate of response to the inactivated trivalent
seasonal inﬂuenza vaccination of 78% [13] similar to that seen
in healthy subjects [14]. Chemotherapy within the previous
4 weeks, or systemic corticosteroid medication had no signiﬁcant
effect on protective HI response. However, no large trials exist to
replicate this information.
Data regarding timing of inﬂuenza vaccination with regard to
chemotherapy administration in adults with solid tumors and
hematological malignancies are limited to three studies: one
published in 1977 [15], two in recent years [4, 16]. Overall, 126
patients have been investigated in such studies. Despite the
paucity of data in a heterogeneous patient population, it can be
suggested that tor patients with solid tumors, if possible, vaccin-
ation should be given mid-cycle, preferably 2 weeks after
chemotherapy and/or before administration of the subsequent
cycle. For patients with hematologic malignancies, the highest
serologic response appears to occur following vaccination
administered when the leukocyte count is normal and just
before initiation of a cycle. In a recently published review article,
Polleya et al. recommend vaccination at the furthest possible
time point away from treatment during a given cycle [17].
Studies, mostly conducted in children, comparing patients
who have completed treatment with those who are still receiving
treatment, show superior responses in those who have ﬁnished
treatment [18–20].
All these studies indicate that, in general, both chemotherapy-
naïve and -treated cancer patients show reduced responses to
inﬂuenza vaccination compared with healthy subjects, but that a
considerable number of cancer patients do actually reach the
cutoff level for seroprotection. Unfortunately, this is not the case
in patients treated with Rituximab in which an impaired
immune response to inﬂuenza vaccine is reported to be asso-
ciated with persistent memory B-cell depletion [21–25]. Thus,
in the context of rituximab-including therapies, alternative or
better-deﬁned prophylactic/therapeutic approaches are needed.
inﬂuenza vaccination in patients with solid tumors
receiving targeted therapies
Limited data are available on the efﬁcacy of inﬂuenza vaccin-
ation in patients receiving immunotherapies or biologic agents
alone or in combination with chemotherapy.
The VACANCE study [26] showed that biologic agents given
in combination with cytotoxic drugs did not seem to negatively
affect seroprotection. In the same study, patients on targeted
therapy alone, especially multikinase inhibitors, had better
immune responses than other treatment groups.
The latter results are in keeping with a recently published
report [27] showing that a single shot of inﬂuenza vaccination is
safe and effective in mounting an antibody immune response in
patients treated with sunitinibor sorafenib, and this immune re-
sponse is comparable with healthy controls. Standard inﬂuenza
vaccination can be therefore recommended for these patients.
strategies to improve the efﬁcacy of inﬂuenza
vaccination
Cancer patients are fragile subjects and inﬂuenza vaccine may
be less effective due to the impaired immune system. For this
reason, they should not be exposed to the LAIV, and the triva-
lent inactivated vaccine is recommended for annual inﬂuenza
prophylaxis. Vaccination against inﬂuenza can reduce severe
illness and complications in immunocompetent individuals, but
data demonstrating vaccine effectiveness in immunocompromised
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individuals are limited [9]. Among HIV-positive people with low
CD4+ T-cell counts, the administration of inactivated trivalent
vaccine does not induce protective antibody titers and a second
dose of vaccine does not improve their immune responses [28].
The lack of beneﬁt of one versus two doses of inactivated
inﬂuenza trivalent vaccine has also been documented in 70
patients with hematological tumors [29].
A recent study [22] demonstrated that two doses of adju-
vanted vaccine A/H1N1 was required in 197 cancer patients
undergoing chemotherapy, to achieve a similar seroprotection
rate (82.3% versus 87%) to that achieved in 138 controls given
one dose.
Aging decreases the immune response after inﬂuenza vaccin-
ation, and adjuvants or higher doses of antigen are supposed to
improve the immune response with better protection against
inﬂuenza. In the VACANCE study, including 65 cancer patients
receiving cytotoxic and/or targeted therapies [4], one or two
doses of AS03A-adjuvanted H1N1v vaccine resulted in seropro-
tection rates of 48% and 73%, respectively, and seroconversion
rates of 44% and 73%, respectively. Thus, two doses of adju-
vanted vaccine improved immunoprotection in this population.
There was no suggestion of a potential detrimental effect on
tumor therapy by the nonspeciﬁc inﬂammatory stimulus due to
adjuvants.
The unique immunological characteristics of the skin with its
dense network of immune-stimulatory antigen-presenting cells,
together with progress in immunization techniques, offer pos-
sible ways of improving immunogenicity in low responders, as
well as reducing dosage in healthy adults [30]. A study by Jo et al.
[31] showed that intradermal injection of one-half the dose of a
trivalent inactivated split vaccine, elicited immune responses
comparable with those elicited by a full dose of intramuscular
vaccine among cancer patients. An open-label study of Fluzone®
high-dose vaccine versus the Fluzone® standard dose is currently
ongoing in children with cancer or HIV receiving two injections
of either dose (www.clinicaltrial.gov: NCT01205581).
Vaccination apart, protection of cancer patients could be
increased by reducing the likelihood of infection. While patients’
isolation is not practically feasible, and would not be ethical,
vaccination of household contacts and health care personnel is
of pivotal importance for increasing the level of herd immunity
in the local environment with consequent reduction of inﬂuenza
virus circulation and likelihood of infection. Moreover, strict
preventive measures should be adopted in oncology wards when
hospitalized patients develop inﬂuenza-like illness, even before
the results of viral testing are known. All hygiene precautions
(hand washing, surgical masks, etc.) should be enforced together
with restrictions on visitors suspected of having respiratory
illness. Leukemic children receiving maintenance chemotherapy
(lasting 2–3 years) have been reported to be more susceptible to
viral infections, probably due to their higher exposure to
infected people during school or daycare contacts. Thus, appro-
priate therapies, together with continued surveillance and im-
plementation of preventive practices, are essential for their care.
antivirals for documented or suspected infection
Antiviral treatment started as soon as there is suspicion of
inﬂuenza may make inﬂuenza infection milder, shorten the
duration of illness, and decrease complications in all populations.
Oseltamivir and zanamivir target the neuraminidase enzyme and
are effective treatments for inﬂuenza infection. Both drugs are
typically given for 5 days, but longer duration of therapy have
been advocated in patients undergoing chemotherapy or with
reduced lymphocyte counts as prolonged viral shedding may
occur in these subjects, and when severe inﬂuenza (i.e. inﬂuenza
pneumonia or illness requiring ICU-level care) is documented
(http://www.cdc.gov/h1n1ﬂu/recommendations.htm).
Antiviral resistance to oseltamivir and zanamivir among cir-
culating inﬂuenza viruses is currently low, but this can emerge
during treatment especially when protracted for long periods
[32, 33]. In patients with cancer who develop fever or inﬂuenza-
like illness, early antiviral therapy should be given empirically
without awaiting laboratory conﬁrmation. On the other hand,
the administration of antiviral drugs may represent the only
feasible strategy for the prevention and treatment of inﬂuenza in
cancer patients who may not beneﬁt from prophylactic vaccin-
ation (e.g. patients receiving rituximab-including therapies).
discussion
It should be emphasized that inﬂuenza vaccination in patients
with cancer is safe, minimally invasive, and inexpensive. The
AIOM recommends vaccination against seasonal inﬂuenza for
cancer patients without contraindications. Both untreated
Table 1. Recommendations and statements on the use of
vaccination for seasonal inﬂuenza in patients with cancer
Inﬂuenza vaccination in patients with cancer is safe, minimally
invasive, and inexpensive.
It should be widely utilized in patients with cancer both untreated
and receiving active therapy, including biologic agents for solid
tumors. The ideal time to administer the vaccination during a
treatment cycle is unclear.
Vaccination of household contacts and health care personnel is
highly recommended as it bears signiﬁcant implications in
increasing the level of herd immunity in the microenvironment
with consequent reduction of inﬂuenza virus circulation
and likelihood of infection.
Strict preventive measures should be adopted in oncology wards in
the presence of hospitalized patients who develop inﬂuenza-like
illness.
Trivalent inactivated vaccine should be given. Data suggest
an increased seroprotection rate by means of vaccines with
adjuvants, an higher doses of antigen, or a second dose of vaccine.
A quadrivalent vaccine has been recently approved by the
United States and European health authorities.
Cancer patients treated with rituximab-containing regimens have
persisting perturbations of B-cell compartments and an impaired
immune response to inﬂuenza vaccine, but also to other common
vaccines. Thus, special efforts are needed to improve preventive/
therapeutic strategies for these refractory patients, including
prophylactic antivirals.
Prospective randomized, controlled trials to better deﬁne the
serological response and the clinical beneﬁts of inﬂuenza
vaccination are needed in this patient population.
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patients and patients undergoing active treatment in any phase
of antineoplastic therapy should be vaccinated. Vaccination of
all household contacts and health care personnel is also recom-
mended. Well-designed prospective studies are needed to iden-
tify optimal immunogenic strategies for seasonal inﬂuenza
vaccination in different clinical conditions, together with
optimal timing of vaccination relative to chemotherapy admin-
istration. A summary of the AIOM recommendations is
reported in Table 1.
funding
Partially supported by Progetto 2011-11961 Associazione
Italiana per la Ricerca sul Cancro (AIRC).
disclosure
The authors have declared no conﬂicts of interest.
references
1. Garten RJ, Davis CT, Russell CA et al. Antigenic and genetic characteristics of
swine-origin 2009 A(H1N1) inﬂuenza viruses circulating in humans. Science
2009; 325: 197–201.
2. Campanini G, Piralla A, Paolucci S et al. Genetic divergence of inﬂuenza A NS1
gene in pandemic 2009 H1N1 isolates with respect to H1N1 and H3N2 isolates
from previous seasonal epidemics. Virol J 2010; 7: 209.
3. Cooksley CD, Avritscher EB, Bekele BN et al. Epidemiology and outcomes of
serious inﬂuenza-related infections in the cancer population. Cancer 2005; 104:
618–628.
4. Meerveld-Eggink A, de Weerdt O, van der Velden AM et al. Response to inﬂuenza
virus vaccination during chemotherapy in patients with breast cancer. Ann Oncol
2011; 22: 2031–2035.
5. Ison MG, Hui DS, Clezy K et al. A clinical trial of intravenous peramivir compared
with oral oseltamivir for the treatment of seasonal inﬂuenza in hospitalized adults.
Antivir Ther 2012; 18: 651–661.
6. Nelson KE. Inﬂuenza vaccine and Guillain-Barre syndrome—is there a risk? Am J
Epidemiol 2012; 175: 1129–1132.
7. Boehmer LM, Waqar SN, Govindan R. Inﬂuenza vaccination in patients with
cancer: an overview. Oncology 2010; 24: 1167–1170.
8. Goossen GM, Kremer LC, van de Wetering MD. Inﬂuenza vaccination in children
being treated with chemotherapy for cancer. Cochrane Database Syst Rev 2013;
8: CD006484. doi: 10.1002/14651858.CD006484.pub3.
9. Rapezzi D, Sticchi L, Racchi O et al. Inﬂuenza vaccine in chronic lymphoproliferative
disorders and multiple myeloma. Eur J Haematol 2003; 70: 225–230.
10. Centkowski P, Brydak L, Machala M et al. Immunogenicity of inﬂuenza vaccination
in patients with non-Hodgkin lymhoma. J Clin Immunol 2007; 27: 339–346.
11. Beck CR, McKenzie BC, Hashim AB et al. Inﬂuenza vaccination for immuno-
compromised patients: systematic review and meta-analysis by aetiology. J Infect
Dis 2012; 206: 1250–1259.
12. Ganz PA, Shanley JD, Cherry JD. Responses of patients with neoplastic diseases
to inﬂuenza virus vaccine. Cancer 1978; 42: 2244–2247.
13. Anderson H, Petrie K, Berrisford C et al. Seroconversion after inﬂuenza vaccination
in patients with lung cancer. Br J Cancer 1999; 80: 219–220.
14. Ring A, Marx G, Steer C et al. Inﬂuenza vaccination and chemotherapy: a shot in
the dark? Support Care Cancer 2002; 10: 462–465.
15. Ortbals DW, Liebhaber H, Presant CA et al. Inﬂuenza immunization of adult
patients with malignant diseases. Ann Intern Med 1977; 87: 552–557.
16. Mackay HJ, McGee J, Villa D et al. Evaluation of pandemic H1N1 (2009) inﬂuenza
vaccine in adults with solid tumor and hematological malignancies on active
systemic treatment. J Clin Virol 2011; 50: 212–216.
17. Pollyea DA, Brown JM, Horning SJ. Utility of inﬂuenza vaccination for oncology
patients. J Clin Oncol 2010; 28: 2481–2490.
18. Gross PA, Lee H, Wolff JA et al. Inﬂuenza immunization in immunosuppressed
children. J Pediatr 1978; 92: 30–35.
19. Steinherz PG, Brown AE, Gross PA et al. Inﬂuenza immunization of children with
neoplastic diseases. Cancer 1980; 45: 750–756.
20. Matsuzaki A, Suminoe A, Koga Y et al. Immune response after inﬂuenza
vaccination in children with cancer. Pediatr Blood Cancer 2005; 45: 831–837.
21. Bedognetti D, Zoppoli G, Massucco C et al. Impaired response to inﬂuenza vaccine
associated with persistent memory B cell depletion in non-Hodgkin’s lymphoma
patients treated with rituximab-containing regimens. J Immunol 2011; 186:
6044–6055.
22. Hottinger AF, George AC, Bel M et al. A prospective study of the factors shaping
antibody responses to the AS03-adjuvanted inﬂuenza A/H1N1 vaccine in cancer
outpatients. Oncologist 2012; 17: 436–445.
23. Issa NC, Marty FM, Gagne LS et al. Seroprotective titers against 2009 H1N1
inﬂuenza A virus after vaccination in allogeneic hematopoietic stem cell
transplantation recipients. Biol Blood Marrow Transplant 2011; 17: 434–438.
24. Yri OE, Torfoss D, Hungnes O et al. Rituximab blocks protective serologic response
to inﬂuenza A (H1N1) 2009 vaccination in lymphoma patients during or within
6 months after treatment. Blood 2011; 118: 6769–6771.
25. Bedognetti D, Ansaldi F, Zanardi E et al. Seasonal and pandemic (A/H1N1 2009)
MF-59-adjuvanted inﬂuenza vaccines in complete remission non-Hodgkin
lymphoma patients previously treated with rituximab containing regimens. Blood
2012; 120: 1954–1957.
26. Rousseau B, Loulergue P, Mir O et al. Immunogenicity and safety of the inﬂuenza
A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy
and/or targeted therapy: the VACANCE study. Ann Oncol 2012; 23: 450–457.
27. Mulder SF, Jacobs JF, Olde Nordkamp MA et al. Cancer patients treated with
sunitinib or sorafenib have sufﬁcient antibody and cellular immune responses to
warrant inﬂuenza vaccination. Clin Cancer Res 2011; 17: 4541–4549.
28. Kroon FP, van Dissel JT, de Jong JC et al. Antibody response after inﬂuenza
vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000;
18: 3040–3049.
29. Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological
malignancies with one or two doses of inﬂuenza vaccine: a randomized study.
Br J. Haematol 2005; 130: 96–98.
30. Ansaldi F, Durando P, Icardi G. Intradermal inﬂuenza vaccine and new devices: a
promising chance for vaccine improvement. Expert Opin Biol Ther 2011; 11:
415–427.
31. Jo YM, Song JY, Hwang IS et al. Dose sparing strategy with intradermal inﬂuenza
vaccination in patients with solid cancer. J Med Virol 2009; 81: 722–727.
32. Campanini G, Piralla A, Rovida F et al. Surveillance Group for New Inﬂuenza
A/H1N1v Investigation in Italy. First case in Italy of acquired resistance to
oseltamivir in an immunocompromised patient with inﬂuenza A/H1N1v infection.
J Clin Virol 2010; 48: 220–222.
33. Esposito S, Molteni CG, Colombo C et al. Oseltamivir-induced resistant pandemic
A/H1N1 inﬂuenza virus in a child with cystic ﬁbrosis and Pseudomonas aeruginosa
infection. J Clin Virol 2010; 48: 62–65.
Volume 25 | No. 6 | June 2014 doi:10.1093/annonc/mdu114 | 
Annals of Oncology original articles
 by guest on N
ovem
ber 27, 2016
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
